Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-188E, GX-I7 and Nivolumab in HPV+ R/M HNSCC
NCT05280457Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Apr 2022
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, Cytokines & Interferons, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tirvalimogene teraplasmid, efineptakin alfa, nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Yonsei University. Started Apr 2022; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05280457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280457.